Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13 by Bolze, Pierre-Adrien, MD, Riedl, Cécilia, MD, Massardier, Jérôme, MD, Lotz, Jean-Pierre, MD, PhD, You, Benoit, MD, PhD, Schott, Anne-Marie, MD, PhD, Hajri, Touria, Ms, Golfier, François, MD, PhD

Get full text

Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity by Chalouhi, Gihad Elias, MD, Golfier, François, MD, PhD, Soignon, Pauline, MD, Massardier, Jerome, MD, Guastalla, Jean-Paul, MD, Trillet-Lenoir, Veronique, MD, Schott, Anne-Marie, MD, PhD, Raudrant, Daniel, MD

Get full text

FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia by Msika, Adrien, Mathias, Virginie, Boudigou, Marina, Chambon, Mathilde, Dubois, Valérie, Hajri, Touria, Lotz, Jean-Pierre, Massardier, Jérôme, Descargues, Pierre, Gladieff, Laurence, Joly, Florence, Lebreton, Coriolan, Maucort-Boulch, Delphine, Bin, Sylvie, Rousset, Pascal, Allias, Fabienne, Gaillot-Durand, Lucie, Devouassoux-Shisheboran, Mojgan, Lemaitre, Nicolas, Alfaidy, Nadia, Langlois-Jacques, Carole, Alves-Ferreira, Marine, Golfier, François, You, Benoit, Thaunat, Olivier, Bolze, Pierre-Adrien, Koenig, Alice

Get full text